Study on the pharmacokinetics of single oral doses of 100 mg and 250 mg roflumilast in children with mild to moderate asthma

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 1, open-label, two-period, increasing dose study in children with mild to moderate asthma.